Investors Purchase High Volume of Put Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of unusually large options trading activity on Monday. Traders acquired 48,643 put options on the company. This is an increase of 19% compared to the typical daily volume of 40,961 put options.

SELLAS Life Sciences Group Stock Down 4.2%

Shares of NASDAQ:SLS traded down $0.33 on Monday, reaching $7.53. The company had a trading volume of 3,178,609 shares, compared to its average volume of 7,843,897. The stock has a market capitalization of $1.52 billion, a P/E ratio of -37.65 and a beta of 2.73. The stock has a 50-day moving average price of $11.03 and a 200 day moving average price of $8.77. SELLAS Life Sciences Group has a twelve month low of $1.39 and a twelve month high of $15.88.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05).

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of large investors have recently added to or reduced their stakes in SLS. Dagco Inc. grew its holdings in SELLAS Life Sciences Group by 19.8% during the second quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock valued at $18,191,000 after purchasing an additional 203,653 shares during the last quarter. Wellington Management Group LLP raised its position in shares of SELLAS Life Sciences Group by 73.2% in the second quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock valued at $8,816,000 after purchasing an additional 252,531 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of SELLAS Life Sciences Group in the second quarter worth $7,823,000. Marshall Wace LLP acquired a new stake in shares of SELLAS Life Sciences Group in the third quarter worth $3,494,000. Finally, Alps Advisors Inc. boosted its holdings in shares of SELLAS Life Sciences Group by 42.2% during the 3rd quarter. Alps Advisors Inc. now owns 267,545 shares of the company’s stock worth $3,293,000 after buying an additional 79,438 shares during the period. Institutional investors own 17.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SLS. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, SELLAS Life Sciences Group has an average rating of “Hold” and an average target price of $10.00.

Read Our Latest Report on SLS

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.

Read More

Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.